Citations (35)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Hadi Mostafaei, Shahrokh F. Shariat, Hanieh Salehi-Pourmehr, Florian Janisch, Keiichiro Mori, Fahad Quhal & Sakineh Hajebrahimi. (2020) The clinical pharmacology of the medical treatment for overactive bladder in adults. Expert Review of Clinical Pharmacology 13:7, pages 707-720.
Read now
Read now
David Mobley, Allison Feibus & Neil Baum. (2015) Benign prostatic hyperplasia and urinary symptoms: Evaluation and treatment. Postgraduate Medicine 127:3, pages 301-307.
Read now
Read now
Mahendra Kashyap & Pradeep Tyagi. (2013) The pharmacokinetic evaluation of mirabegron as an overactive bladder therapy option. Expert Opinion on Drug Metabolism & Toxicology 9:5, pages 617-627.
Read now
Read now
Articles from other publishers (32)
Anirban Ganguly, Shachi Tyagi, Christopher Chermansky, Anthony Kanai, Jonathan Beckel, Mamoru Hashimoto, Kang Jun Cho, Michael Chancellor, Jonathan Kaufman, Naoki Yoshimura & Pradeep Tyagi. (2023) Treating Lower Urinary Tract Symptoms in Older Adults: Intravesical Options. Drugs & Aging 40:3, pages 241-261.
Crossref
Crossref
Tanja Hüsch, André Reitz, Laila Schneidewind & Jennifer Kranz. (2021) 32/w mit irritativen Miktionsbeschwerden32/f with lower urinary tract symptoms. Der Urologe 61:S2, pages 56-62.
Crossref
Crossref
Kritika Laxmikeshav, Pooja Kumari & Nagula Shankaraiah. (2021) Expedition of sulfur‐containing heterocyclic derivatives as cytotoxic agents in medicinal chemistry: A decade update. Medicinal Research Reviews 42:1, pages 513-575.
Crossref
Crossref
Pankaj Mandpe, Bala Prabhakar & Pravin Shende. (2019) 23 Full factorial design for optimization of stable amorphous host–guest-based mirabegron complex for extended-release action. Journal of Inclusion Phenomena and Macrocyclic Chemistry 96:1-2, pages 111-123.
Crossref
Crossref
Andrzej Wróbel, Barbara Miziak, Małgorzata Bańczerowska‐Górska, Aleksandra Szopa, Anna Serefko, Klaudia Stangel‐Wójcikiewicz, Piotr Czuczwar, Marzena Laskowska, Edyta Wlaźlak, Jarosław Dudka & Ewa Poleszak. (2019) The influence of nebivolol on the activity of BRL 37344 — the β3‐adrenergic receptor agonist, in the animal model of detrusor overactivity. Neurourology and Urodynamics 38:5, pages 1229-1240.
Crossref
Crossref
Blayne Welk, Duane Hickling, Mary McKibbon, Sidney Radomski & Karen Ethans. (2018) A pilot randomized-controlled trial of the urodynamic efficacy of mirabegron for patients with neurogenic lower urinary tract dysfunction. Neurourology and Urodynamics 37:8, pages 2810-2817.
Crossref
Crossref
Renee D. Schmid & Lynn R. Hovda. (2017) Mirabegron Toxicosis in Dogs: a Retrospective Study. Journal of Medical Toxicology 14:2, pages 160-167.
Crossref
Crossref
Larry Yet. 2018. Privileged Structures in Drug Discovery. Privileged Structures in Drug Discovery
284
320
.
Yasuhiro Wada, Seiji Nakano, Akifumi Morimoto, Ken-ichi Kasahara, Takahiko Hayashi, Yoshio Takada, Hiroko Suzuki, Michiko Niwa-Sakai, Shigeki Ohashi, Mutsuhiro Mori, Takatsugu Hirokawa & Satoshi Shuto. (2017)
Discovery of Novel Indazole Derivatives as Orally Available β
3
-Adrenergic Receptor Agonists Lacking Off-Target-Based Cardiovascular Side Effects
. Journal of Medicinal Chemistry 60:8, pages 3252-3265.
Crossref
Crossref
Henning Bundgaard, Anna Axelsson, Jakob Hartvig Thomsen, Mathias Sørgaard, Klaus F. Kofoed, Rasmus Hasselbalch, Natasha A.S. Fry, Nana Valeur, Søren Boesgaard, Finn Gustafsson, Lars Køber, Kasper Iversen & Helge H. Rasmussen. (2017) The first-in-man randomized trial of a beta3 adrenoceptor agonist in chronic heart failure: the BEAT-HF trial. European Journal of Heart Failure 19:4, pages 566-575.
Crossref
Crossref
S.D. Edmondson. 2017. Comprehensive Medicinal Chemistry III. Comprehensive Medicinal Chemistry III
714
737
.
Ryuji Sakakibara, Jalesh Panicker, Enrico Finazzi-Agro, Valerio Iacovelli & Homero Bruschini. (2016) A guideline for the management of bladder dysfunction in Parkinson's disease and other gait disorders. Neurourology and Urodynamics 35:5, pages 551-563.
Crossref
Crossref
Yasuhiro Wada, Hiromitsu Shirahashi, Taisuke Iwanami, Masami Ogawa, Seiji Nakano, Akifumi Morimoto, Ken-ichi Kasahara, Eiichi Tanaka, Yoshio Takada, Shigeki Ohashi, Mutsuhiro Mori & Satoshi Shuto. (2015)
Discovery of Novel Indazole Derivatives as Highly Potent and Selective Human β
3
-Adrenergic Receptor Agonists with the Possibility of Having No Cardiovascular Side Effects
. Journal of Medicinal Chemistry 58:15, pages 6048-6057.
Crossref
Crossref
Fuyuki Tateno, Ryuji Sakakibara, Tsuyoshi Ogata, Masahiko Kishi, Yohei Tsuyusaki, Osamu Takahashi, Megumi Sugiyama & Akihiko Tateno. (2014) Lower urinary tract function in dementia with Lewy bodies (DLB). Movement Disorders 30:3, pages 411-415.
Crossref
Crossref
Pradipbhai D. Kalariya, Mahesh Sharma, Prabha Garg, Jagadeshwar Reddy Thota, Srinivas Ragampeta & M. V. N. Kumar Talluri. (2015) Characterization of stress degradation products of mirabegron using UPLC-QTOF-MS/MS and in silico toxicity predictions of its degradation products. RSC Advances 5:39, pages 31024-31038.
Crossref
Crossref
Ryuji Sakakibara. 2015. Neurology of Sexual and Bladder Disorders. Neurology of Sexual and Bladder Disorders
269
287
.
Lucio M.A. Cipullo, Cosimo Cosimato, Amelia Filippelli, Valeria Conti, Viviana Izzo, Fulvio Zullo & Maurizio Guida. (2014) Pharmacological approach to overactive bladder and urge urinary incontinence in women: an overview. European Journal of Obstetrics & Gynecology and Reproductive Biology 174, pages 27-34.
Crossref
Crossref
Tao Wu, Xi Duan, Chen-Xi Cao, Chuan-Du Peng, Si-Yuan Bu & Kun-Jie Wang. (2014) The Role of Mirabegron in Overactive Bladder: A Systematic Review and Meta-Analysis. Urologia Internationalis 93:3, pages 326-337.
Crossref
Crossref
Ryuji Sakakibara, Jalesh Panicker, Clare J Fowler, Fuyuki Tateno, Masahiko Kishi, Yohei Tsuyusaki, Tomonori Yamanishi, Tomoyuki Uchiyama, Tatsuya Yamamoto & Masashi Yano. (2014) Is overactive bladder a brain disease? The pathophysiological role of cerebral white matter in the elderly. International Journal of Urology 21:1, pages 33-38.
Crossref
Crossref
Jamie M. Bartley, Emily S. Blum, Larry T. Sirls & Kenneth M. Peters. (2013) Understanding Clinic Options for Overactive Bladder. Current Urology Reports 14:6, pages 541-548.
Crossref
Crossref
Victor W. Nitti, Steven Rosenberg, David H. Mitcheson, Weizhong He, Allam Fakhoury & Nancy E. Martin. (2013)
Urodynamics and Safety of the β
3
-Adrenoceptor Agonist Mirabegron in Males with Lower Urinary Tract Symptoms and Bladder Outlet Obstruction
. Journal of Urology 190:4, pages 1320-1327.
Crossref
Crossref
Ryuji SAKAKIBARA, Takashi ITO, Tatsuya YAMAMOTO, Tomoyuki UCHIYAMA, Tomonori YAMANISHI, Masahiko KISHI, Yohei TSUYUSAKI, Fuyuki TATENO, Shuichi KATSURAGAWA & Nobuo KUROKI. (2013) Depression, Anxiety and the Bladder. LUTS: Lower Urinary Tract Symptoms 5:3, pages 109-120.
Crossref
Crossref
Gary D. NovackRichard A. LewisRoger VogelNeha ShethDennis SwearingenScott RasmussenGary HantsbargerNancy E. Martin. (2013) Randomized, Double-Masked, Placebo-Controlled Study to Assess the Ocular Safety of Mirabegron in Healthy Volunteers. Journal of Ocular Pharmacology and Therapeutics 29:7, pages 674-680.
Crossref
Crossref
. (2013) ▼Mirabegron for overactive bladder syndrome:. Drug and Therapeutics Bulletin 51:8, pages 90-92.
Crossref
Crossref
Hong X. Ding, Kevin K.-C. Liu, Subas M. Sakya, Andrew C. Flick & Christopher J. O’Donnell. (2013) Synthetic approaches to the 2011 new drugs. Bioorganic & Medicinal Chemistry 21:11, pages 2795-2825.
Crossref
Crossref
Joy A. Greer, Lily A. Arya & Ariana L. Smith. (2013) Urinary Incontinence: Diagnosis and Treatment in the Elderly. Current Translational Geriatrics and Experimental Gerontology Reports 2:2, pages 66-75.
Crossref
Crossref
Adrian Wagg. (2012) Fesoterodine fumarate for the treatment of overactive bladder in the elderly – a review of the latest clinical data. Clinical Investigation 2:8, pages 825-833.
Crossref
Crossref
Jack Humphrey. (2012) How Drugs Modify The Micturition Reflex: A Review. Opticon1826 7:12, pages 9.
Crossref
Crossref
Sayoko Kanie, Atsushi Otsuka, Satoru Yoshikawa, Takashi Morimoto, Nana Hareyama, Seiji Okazaki, Ryosuke Kobayashi, Ko Hasebe, Kaoru Nakao, Ryoji Hayashi, Hidenori Mochizuki, Rikiya Matsumoto & Seiichiro Ozono. (2012) Pharmacological Effect of TRK-380, a Novel Selective Human β3-Adrenoceptor Agonist, on Mammalian Detrusor Strips. Urology 79:3, pages 744.e1-744.e7.
Crossref
Crossref
Altaf Mangera & Christopher R. Chapple. (2011) Summary of Anticholinergic Pharmacotherapy Available for Overactive Bladder Dysfunction. Current Bladder Dysfunction Reports 7:1, pages 51-58.
Crossref
Crossref
Anthony Kanai, Irina Zabbarova, Michael Oefelein, Piotr Radziszewski, Youko Ikeda & Karl‐Erik Andersson. (2012)
Mechanisms of action of botulinum neurotoxins, β
3
‐adrenergic receptor agonists, and PDE5 inhibitors in modulating detrusor function in overactive bladders: ICI‐RS 2011
. Neurourology and Urodynamics 31:3, pages 300-308.
Crossref
Crossref
Fotios Dimitriadis, Motoaki Saito, Fumiya Ohmasa, Seiya Inoue & Keisuke Satoh. (2011) A β3 Agonist, Mirabegron for the Treatment of Overactive Bladder. UroToday International Journal 04:06.
Crossref
Crossref